AUSTIN, Texas, Nov. 27, 2012 /PRNewswire/ -- Luminex Corporation
(NASDAQ: LMNX) will host an investor event in New York City on Tuesday, December 11, 2012 beginning at
8am ET, as previously announced on
its third quarter financial results conference call.
(Logo:
http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)
Patrick J. Balthrop, president
and chief executive officer, and other members of the executive
management team will provide insight into the company's long-term
strategic plans with a focus on its molecular diagnostic product
pipeline.
Advanced registration is required and attendance will be limited
to those registered. To register, please contact Matthew Scalo, Senior Director of Investor
Relations. Breakfast will be served beginning at 7am ET.
The presentation will be webcast live and may be accessed
at Luminex Corporation's website at http://www.luminexcorp.com.
Simply log on to the web at the address above, go to the
Company section and access the Investor Relations link.
Please go to the website at least 15 minutes prior to the
event to register, download and install any necessary audio/video
software. If you are unable to participate during the live webcast,
the presentation will be archived on the website using the 'replay'
link.
Luminex is committed to applying its passion for innovation
toward advancing healthcare and research worldwide. We are
transforming global healthcare and life-science research through
the development, manufacturing, and marketing of proprietary
instruments and assays utilizing our xMAP® open-architecture,
multi-analyte platform and our MultiCode® real-time polymerase
chain reaction (PCR) and multiplex PCR-based technologies that
deliver cost-effective and rapid results to clinicians and
researchers. Our technology is commercially available worldwide and
in use in leading clinical laboratories as well as major
pharmaceutical, diagnostic, biotechnology and life-science
companies. We are meeting the needs of customers in markets
as diverse as clinical diagnostics, pharmaceutical drug discovery,
biomedical research including genomic and proteomic research,
personalized medicine, bio-defense research and food safety.
For further information on Luminex Corporation and the latest
advances in multiplexing using award winning technology please
visit our website at http://www.luminexcorp.com.
Contacts:
|
Matthew
Scalo
|
|
Sr.
Director of Investor Relations
|
|
512-219-8020
|
|
mscalo@luminexcorp.com
|
SOURCE Luminex Corporation